D.A. Davidson & CO. boosted its position in shares of Shire PLC (NASDAQ:SHPG) by 18.9% in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 14,141 shares of the biopharmaceutical company’s stock after acquiring an additional 2,251 shares during the period. D.A. Davidson & CO.’s holdings in Shire PLC were worth $2,337,000 as of its most recent SEC filing.

A number of other large investors have also recently modified their holdings of the stock. Rafferty Asset Management LLC grew its stake in Shire PLC by 34.0% during the second quarter. Rafferty Asset Management LLC now owns 8,681 shares of the biopharmaceutical company’s stock valued at $1,435,000 after acquiring an additional 2,204 shares in the last quarter. PNC Financial Services Group Inc. grew its stake in Shire PLC by 1.9% during the second quarter. PNC Financial Services Group Inc. now owns 147,777 shares of the biopharmaceutical company’s stock valued at $24,422,000 after acquiring an additional 2,750 shares in the last quarter. Ameriprise Financial Inc. grew its stake in Shire PLC by 14.7% during the second quarter. Ameriprise Financial Inc. now owns 1,510,227 shares of the biopharmaceutical company’s stock valued at $249,577,000 after acquiring an additional 194,059 shares in the last quarter. Icon Advisers Inc. Co. grew its stake in Shire PLC by 43.8% during the second quarter. Icon Advisers Inc. Co. now owns 59,100 shares of the biopharmaceutical company’s stock valued at $9,767,000 after acquiring an additional 18,000 shares in the last quarter. Finally, Seven Eight Capital LP grew its stake in Shire PLC by 18.5% during the second quarter. Seven Eight Capital LP now owns 4,494 shares of the biopharmaceutical company’s stock valued at $743,000 after acquiring an additional 700 shares in the last quarter. 19.28% of the stock is owned by institutional investors.

Shares of Shire PLC (SHPG) opened at 155.0900 on Friday. Shire PLC has a 52 week low of $139.36 and a 52 week high of $206.94.

Shire PLC (NASDAQ:SHPG) last posted its earnings results on Friday, October 27th. The biopharmaceutical company reported $3.37 earnings per share for the quarter, missing analysts’ consensus estimates of $3.66 by ($0.29). Shire PLC had a net margin of 4.70% and a return on equity of 14.10%. On average, equities analysts predict that Shire PLC will post $14.93 earnings per share for the current year.

The firm also recently announced a semiannual dividend, which will be paid on Friday, October 20th. Investors of record on Friday, September 8th will be issued a $0.1527 dividend. This represents a dividend yield of 0.21%. The ex-dividend date is Thursday, September 7th. Shire PLC’s dividend payout ratio (DPR) is presently 41.07%.

Several equities analysts recently commented on the stock. Cantor Fitzgerald reaffirmed a “buy” rating and set a $222.00 price objective on shares of Shire PLC in a research note on Thursday, September 14th. ValuEngine cut shares of Shire PLC from a “buy” rating to a “hold” rating in a research note on Friday, September 1st. Evercore ISI assumed coverage on shares of Shire PLC in a research note on Wednesday, August 16th. They set an “outperform” rating and a $196.00 price objective for the company. Barclays PLC cut shares of Shire PLC from an “overweight” rating to an “equal weight” rating in a research note on Friday, August 11th. Finally, Jefferies Group LLC reaffirmed a “hold” rating and set a $206.00 price objective (down previously from $216.00) on shares of Shire PLC in a research note on Wednesday, August 9th. One equities research analyst has rated the stock with a sell rating, ten have assigned a hold rating and fourteen have given a buy rating to the stock. The stock has a consensus rating of “Buy” and an average target price of $220.08.

ILLEGAL ACTIVITY NOTICE: This piece was first reported by Daily Political and is the property of of Daily Political. If you are viewing this piece on another publication, it was stolen and reposted in violation of U.S. and international copyright legislation. The correct version of this piece can be viewed at https://www.dailypolitical.com/2017/09/23/shire-plc-shpg-position-boosted-by-d-a-davidson-co.html.

About Shire PLC

Shire plc is a biotech company focused on serving people with rare diseases and other specialized conditions. The Company’s segment is engaged in research, development, licensing, manufacturing, marketing, distribution and sale of specialist medicines. It focuses its development resources on projects in various therapeutic areas (TAs), including Neuroscience, Ophthalmology, Hematology, Oncology, Immunology, Gastrointestinal (GI)/Metabolic/Endocrinology Diseases.

Want to see what other hedge funds are holding SHPG? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Shire PLC (NASDAQ:SHPG).

Institutional Ownership by Quarter for Shire PLC (NASDAQ:SHPG)

Receive News & Ratings for Shire PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Shire PLC and related companies with MarketBeat.com's FREE daily email newsletter.